REGENERON PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 955.8 USD | -1.46% |
|
+5.79% | +8.82% |
Presenter SpeechRobyn Karnauskas (Analysts)Good morning, everyone. What a delight to have Dr. ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:
- revenues from product sales (56.6%);
- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);
- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.
At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
955.8
USD
Average target price
1,034
USD
Spread / Average Target
+8.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.82% | 105B | |
| +2.93% | 108B | |
| -0.90% | 23.46B | |
| -14.60% | 21.72B | |
| -7.05% | 18.64B | |
| -38.55% | 17.45B | |
| -8.83% | 17.19B | |
| +5.51% | 13.99B | |
| +37.49% | 12.53B | |
| +329.39% | 8.81B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Transcript : Regeneron Pharmaceuticals, Inc. Presents at Truist Securities 2023 BioPharma Symposium, Nov-08-2023 03